Last updated on November 2018

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Malignant neoplasm of prostate
  • Age: Between 18 - 100 Years
  • Gender: Male

Key Inclusion Criteria:

  1. Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate;
  2. Is a candidate for, in the opinion of the investigator, at least 1 year of continuous androgen deprivation therapy for the management of androgen-sensitive advanced prostate cancer with one of the following clinical disease state presentations:
  3. Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery; or
  4. Newly diagnosed androgen-sensitive metastatic disease; or
  5. Advanced localized disease unlikely to be cured by local primary intervention with either surgery or radiation with curative intent

Note: Once 915 patients are enrolled worldwide only patients with metastatic advanced prostate cancer will be eligible for the study in all regions except China, where both metastatic and non-metastatic patients will continue to be enrolled.

3. Has a serum testosterone at the Screening visit of 150 ng/dL (5.2 nmol/L);

4. Has a serum PSA concentration at the Screening visit of > 2.0 ng/mL (2.0 g/L), or, when applicable, post radical prostatectomy of > 0.2 ng/mL (0.2 g/L) or post radiotherapy, cryotherapy, or high frequency ultrasound > 2.0 ng/mL (2.0 g/L) above the post interventional nadir;

5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at initial screening and at baseline.

Key Exclusion Criteria:

  1. In the investigator's opinion, is likely to require chemotherapy or surgical therapy for symptomatic disease management within 2 months of initiating androgen deprivation therapy;
  2. Previously received GnRH analog or other form of androgen deprivation therapy (estrogen or antiandrogen) for > 18 months total duration. If androgen deprivation therapy was received for 18 months total duration, then that therapy must have been completed at least 3 months prior to baseline. If the dosing interval of the depot is longer than 3 months, then the prior androgen deprivation therapy must have been completed at least as long as the dosing interval of the depot;
  3. Previous systemic cytotoxic treatment for prostate cancer (eg: taxane-based regimen);
  4. Metastases to brain per prior clinical evaluation;
  5. Scheduled for major surgery after baseline;
  6. History of surgical castration.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.